Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 62

1.

Treatment of a first patient with FLASH-radiotherapy.

Bourhis J, Sozzi WJ, Jorge PG, Gaide O, Bailat C, Duclos F, Patin D, Ozsahin M, Bochud F, Germond JF, Moeckli R, Vozenin MC.

Radiother Oncol. 2019 Jul 11. pii: S0167-8140(19)32959-7. doi: 10.1016/j.radonc.2019.06.019. [Epub ahead of print]

PMID:
31303340
2.

Clinical translation of FLASH radiotherapy: Why and how?

Bourhis J, Montay-Gruel P, Gonçalves Jorge P, Bailat C, Petit B, Ollivier J, Jeanneret-Sozzi W, Ozsahin M, Bochud F, Moeckli R, Germond JF, Vozenin MC.

Radiother Oncol. 2019 Jun 25. pii: S0167-8140(19)30360-3. doi: 10.1016/j.radonc.2019.04.008. [Epub ahead of print]

PMID:
31253466
3.

Dosimetric and preparation procedures for irradiating biological models with pulsed electron beam at ultra-high dose-rate.

Jorge PG, Jaccard M, Petersson K, Gondré M, Durán MT, Desorgher L, Germond JF, Liger P, Vozenin MC, Bourhis J, Bochud F, Moeckli R, Bailat C.

Radiother Oncol. 2019 Jun 4. pii: S0167-8140(19)30403-7. doi: 10.1016/j.radonc.2019.05.004. [Epub ahead of print]

PMID:
31174897
4.

TRIM33 deficiency in monocytes and macrophages impairs resolution of colonic inflammation.

Petit V, Parcelier A, Mathé C, Barroca V, Torres C, Lewandowski D, Ferri F, Gallouët AS, Dalloz M, Dinet O, Boschetti G, Vozenin MC, Roméo PH.

EBioMedicine. 2019 Jun;44:60-70. doi: 10.1016/j.ebiom.2019.05.037. Epub 2019 May 24.

5.

[Management of refractory ventricular tachycardia using stereotactic body radiotherapy].

Jumeau R, Bourhis J, Ozsahin M, Vallet V, Zeverino M, Moeckli R, Kinj R, Vozenin MC, Schwitter J, Herrera-Siklody C, Pascale P, Pruvot É.

Rev Med Suisse. 2019 May 22;15(652):1082-1086. French.

PMID:
31116523
6.

Long-term neurocognitive benefits of FLASH radiotherapy driven by reduced reactive oxygen species.

Montay-Gruel P, Acharya MM, Petersson K, Alikhani L, Yakkala C, Allen BD, Ollivier J, Petit B, Jorge PG, Syage AR, Nguyen TA, Baddour AAD, Lu C, Singh P, Moeckli R, Bochud F, Germond JF, Froidevaux P, Bailat C, Bourhis J, Vozenin MC, Limoli CL.

Proc Natl Acad Sci U S A. 2019 May 28;116(22):10943-10951. doi: 10.1073/pnas.1901777116. Epub 2019 May 16.

7.

Isodose 20 Gy found as a threshold dose for radiation recall dermatitis.

Scher N, Vozenin MC, Bouchaab H, Ozsahin M, Bourhis J.

Clin Transl Radiat Oncol. 2019 Apr 11;17:14-16. doi: 10.1016/j.ctro.2019.03.003. eCollection 2019 Jul.

8.

Biological Benefits of Ultra-high Dose Rate FLASH Radiotherapy: Sleeping Beauty Awoken.

Vozenin MC, Hendry JH, Limoli CL.

Clin Oncol (R Coll Radiol). 2019 Jul;31(7):407-415. doi: 10.1016/j.clon.2019.04.001. Epub 2019 Apr 19.

PMID:
31010708
9.

[Cardiac toxicity induced by radiation therapy: a reality to consider].

Vozenin MC.

Rev Prat. 2018 Mar;68(3):330-331. French. No abstract available.

PMID:
30869301
10.

Pravastatin Reverses Established Radiation-Induced Cutaneous and Subcutaneous Fibrosis in Patients With Head and Neck Cancer: Results of the Biology-Driven Phase 2 Clinical Trial Pravacur.

Bourgier C, Auperin A, Rivera S, Boisselier P, Petit B, Lang P, Lassau N, Taourel P, Tetreau R, Azria D, Bourhis J, Deutsch E, Vozenin MC.

Int J Radiat Oncol Biol Phys. 2019 Jun 1;104(2):365-373. doi: 10.1016/j.ijrobp.2019.02.024. Epub 2019 Feb 15.

PMID:
30776452
11.

Emerging Opportunities of Radiotherapy Combined With Immunotherapy in the Era of Breast Cancer Heterogeneity.

Tsoutsou PG, Zaman K, Martin Lluesma S, Cagnon L, Kandalaft L, Vozenin MC.

Front Oncol. 2018 Dec 12;8:609. doi: 10.3389/fonc.2018.00609. eCollection 2018. Review.

12.

Circulating Tumor Cells and Radiotherapy Benefit in Early Breast Cancer.

Tsoutsou PG, Vozenin MC.

JAMA Oncol. 2019 Jan 1;5(1):111-112. doi: 10.1001/jamaoncol.2018.5077. No abstract available.

PMID:
30476960
13.

Fibrosis Development in HOCl-Induced Systemic Sclerosis: A Multistage Process Hampered by Mesenchymal Stem Cells.

Maria ATJ, Toupet K, Maumus M, Rozier P, Vozenin MC, Le Quellec A, Jorgensen C, Noël D, Guilpain P.

Front Immunol. 2018 Nov 5;9:2571. doi: 10.3389/fimmu.2018.02571. eCollection 2018.

14.

X-rays can trigger the FLASH effect: Ultra-high dose-rate synchrotron light source prevents normal brain injury after whole brain irradiation in mice.

Montay-Gruel P, Bouchet A, Jaccard M, Patin D, Serduc R, Aim W, Petersson K, Petit B, Bailat C, Bourhis J, Bräuer-Krisch E, Vozenin MC.

Radiother Oncol. 2018 Dec;129(3):582-588. doi: 10.1016/j.radonc.2018.08.016. Epub 2018 Aug 31.

PMID:
30177374
15.

Cellular Composition and Contribution of Tertiary Lymphoid Structures to Tumor Immune Infiltration and Modulation by Radiation Therapy.

Boivin G, Kalambaden P, Faget J, Rusakiewicz S, Montay-Gruel P, Meylan E, Bourhis J, Lesec G, Vozenin MC.

Front Oncol. 2018 Jul 9;8:256. doi: 10.3389/fonc.2018.00256. eCollection 2018.

16.

The Advantage of FLASH Radiotherapy Confirmed in Mini-pig and Cat-cancer Patients.

Vozenin MC, De Fornel P, Petersson K, Favaudon V, Jaccard M, Germond JF, Petit B, Burki M, Ferrand G, Patin D, Bouchaab H, Ozsahin M, Bochud F, Bailat C, Devauchelle P, Bourhis J.

Clin Cancer Res. 2019 Jan 1;25(1):35-42. doi: 10.1158/1078-0432.CCR-17-3375. Epub 2018 Jun 6.

17.

Experimental Drainage Device to Reduce Lymphoedema in a Rat Model.

Triacca V, Pisano M, Lessert C, Petit B, Bouzourene K, Nahimana A, Vozenin MC, Stergiopulos N, Swartz MA, Mazzolai L.

Eur J Vasc Endovasc Surg. 2019 Jun;57(6):859-867. doi: 10.1016/j.ejvs.2018.04.014. Epub 2018 May 25.

18.

Expanding the therapeutic index of radiation therapy by normal tissue protection.

Montay-Gruel P, Meziani L, Yakkala C, Vozenin MC.

Br J Radiol. 2018 Jul 2:20180008. doi: 10.1259/bjr.20180008. [Epub ahead of print]

PMID:
29694234
19.

CSF1R inhibition prevents radiation pulmonary fibrosis by depletion of interstitial macrophages.

Meziani L, Mondini M, Petit B, Boissonnas A, Thomas de Montpreville V, Mercier O, Vozenin MC, Deutsch E.

Eur Respir J. 2018 Mar 1;51(3). pii: 1702120. doi: 10.1183/13993003.02120-2017. Print 2018 Mar.

20.

High dose-per-pulse electron beam dosimetry: Commissioning of the Oriatron eRT6 prototype linear accelerator for preclinical use.

Jaccard M, Durán MT, Petersson K, Germond JF, Liger P, Vozenin MC, Bourhis J, Bochud F, Bailat C.

Med Phys. 2018 Feb;45(2):863-874. doi: 10.1002/mp.12713. Epub 2018 Jan 6.

PMID:
29206287
21.

A need for biology-driven personalized radiotherapy in breast cancer.

Tsoutsou PG, Durham AD, Vozenin MC.

Breast Cancer Res Treat. 2018 Jan;167(2):603-604. doi: 10.1007/s10549-017-4522-z. Epub 2017 Sep 27. No abstract available.

PMID:
28952059
22.

Irradiation in a flash: Unique sparing of memory in mice after whole brain irradiation with dose rates above 100Gy/s.

Montay-Gruel P, Petersson K, Jaccard M, Boivin G, Germond JF, Petit B, Doenlen R, Favaudon V, Bochud F, Bailat C, Bourhis J, Vozenin MC.

Radiother Oncol. 2017 Sep;124(3):365-369. doi: 10.1016/j.radonc.2017.05.003. Epub 2017 May 22.

PMID:
28545957
23.

Cardiac Radionuclide Imaging in Rodents: A Review of Methods, Results, and Factors at Play.

Cicone F, Viertl D, Quintela Pousa AM, Denoël T, Gnesin S, Scopinaro F, Vozenin MC, Prior JO.

Front Med (Lausanne). 2017 Mar 29;4:35. doi: 10.3389/fmed.2017.00035. eCollection 2017.

24.

TAT-RasGAP317-326 Enhances Radiosensitivity of Human Carcinoma Cell Lines In Vitro and In Vivo through Promotion of Delayed Mitotic Cell Death.

Tsoutsou P, Annibaldi A, Viertl D, Ollivier J, Buchegger F, Vozenin MC, Bourhis J, Widmann C, Matzinger O.

Radiat Res. 2017 May;187(5):562-569. doi: 10.1667/RR14509.1. Epub 2017 Mar 21.

PMID:
28323576
25.

[Hopes of high dose-rate radiotherapy].

Fouillade C, Favaudon V, Vozenin MC, Romeo PH, Bourhis J, Verrelle P, Devauchelle P, Patriarca A, Heinrich S, Mazal A, Dutreix M.

Bull Cancer. 2017 Apr;104(4):380-384. doi: 10.1016/j.bulcan.2017.01.012. Epub 2017 Mar 7. Review. French.

PMID:
28283183
26.

How could breast cancer molecular features contribute to locoregional treatment decision making?

Tsoutsou PG, Vozenin MC, Durham AD, Bourhis J.

Crit Rev Oncol Hematol. 2017 Feb;110:43-48. doi: 10.1016/j.critrevonc.2016.12.006. Epub 2016 Dec 8. Review.

PMID:
28109404
27.

High dose-per-pulse electron beam dosimetry - A model to correct for the ion recombination in the Advanced Markus ionization chamber.

Petersson K, Jaccard M, Germond JF, Buchillier T, Bochud F, Bourhis J, Vozenin MC, Bailat C.

Med Phys. 2017 Mar;44(3):1157-1167. doi: 10.1002/mp.12111. Epub 2017 Feb 28.

PMID:
28094853
28.

High dose-per-pulse electron beam dosimetry: Usability and dose-rate independence of EBT3 Gafchromic films.

Jaccard M, Petersson K, Buchillier T, Germond JF, Durán MT, Vozenin MC, Bourhis J, Bochud FO, Bailat C.

Med Phys. 2017 Feb;44(2):725-735. doi: 10.1002/mp.12066. Epub 2017 Feb 8.

PMID:
28019660
29.

PrP(c) deficiency and dasatinib protect mouse intestines against radiation injury by inhibiting of c-Src.

Strup-Perrot C, Vozenin MC, Monceau V, Pouzoulet F, Petit B, Holler V, Perrot S, Desquibert L, Fouquet S, Souquere S, Pierron G, Rousset M, Thenet S, Cardot P, Benderitter M, Deutsch E, Aigueperse J.

Radiother Oncol. 2016 Jul;120(1):175-83. doi: 10.1016/j.radonc.2016.06.009. Epub 2016 Jul 9.

PMID:
27406443
30.

Comparison between Stromal Vascular Fraction and Adipose Mesenchymal Stem Cells in Remodeling Hypertrophic Scars.

Domergue S, Bony C, Maumus M, Toupet K, Frouin E, Rigau V, Vozenin MC, Magalon G, Jorgensen C, Noël D.

PLoS One. 2016 May 26;11(5):e0156161. doi: 10.1371/journal.pone.0156161. eCollection 2016.

31.

Antifibrotic, Antioxidant, and Immunomodulatory Effects of Mesenchymal Stem Cells in HOCl-Induced Systemic Sclerosis.

Maria AT, Toupet K, Bony C, Pirot N, Vozenin MC, Petit B, Roger P, Batteux F, Le Quellec A, Jorgensen C, Noël D, Guilpain P.

Arthritis Rheumatol. 2016 Apr;68(4):1013-25. doi: 10.1002/art.39477.

32.

[Ultrahigh dose-rate, "flash" irradiation minimizes the side-effects of radiotherapy].

Favaudon V, Fouillade C, Vozenin MC.

Cancer Radiother. 2015 Oct;19(6-7):526-31. doi: 10.1016/j.canrad.2015.04.006. Epub 2015 Aug 12. French.

PMID:
26277238
33.

The radiosensitizing activity of the SMAC-mimetic, Debio 1143, is TNFα-mediated in head and neck squamous cell carcinoma.

Matzinger O, Viertl D, Tsoutsou P, Kadi L, Rigotti S, Zanna C, Wiedemann N, Vozenin MC, Vuagniaux G, Bourhis J.

Radiother Oncol. 2015 Sep;116(3):495-503. doi: 10.1016/j.radonc.2015.05.017. Epub 2015 Jun 18.

PMID:
26096848
34.

Synergy of Radiotherapy and a Cancer Vaccine for the Treatment of HPV-Associated Head and Neck Cancer.

Mondini M, Nizard M, Tran T, Mauge L, Loi M, Clémenson C, Dugue D, Maroun P, Louvet E, Adam J, Badoual C, Helley D, Dransart E, Johannes L, Vozenin MC, Perfettini JL, Tartour E, Deutsch E.

Mol Cancer Ther. 2015 Jun;14(6):1336-45. doi: 10.1158/1535-7163.MCT-14-1015. Epub 2015 Apr 1.

35.

[The radiotherapy FLASH to save healthy tissues].

Favaudon V, Fouillade C, Vozenin MC.

Med Sci (Paris). 2015 Feb;31(2):121-3. doi: 10.1051/medsci/20153102002. Epub 2015 Mar 4. French. No abstract available.

36.

Cytotoxic effect of lapatinib is restricted to human papillomavirus-positive head and neck squamous cell carcinoma cell lines.

Fumagalli I, Dugue D, Bibault JE, Clémenson C, Vozenin MC, Mondini M, Deutsch E.

Onco Targets Ther. 2015 Feb 2;8:335-45. doi: 10.2147/OTT.S68235. eCollection 2015.

37.

Simultaneous irradiation of fibroblasts and carcinoma cells repress the secretion of soluble factors able to stimulate carcinoma cell migration.

Arshad A, Deutsch E, Vozenin MC.

PLoS One. 2015 Jan 30;10(1):e0115447. doi: 10.1371/journal.pone.0115447. eCollection 2015.

38.

Ultrahigh dose-rate FLASH irradiation increases the differential response between normal and tumor tissue in mice.

Favaudon V, Caplier L, Monceau V, Pouzoulet F, Sayarath M, Fouillade C, Poupon MF, Brito I, Hupé P, Bourhis J, Hall J, Fontaine JJ, Vozenin MC.

Sci Transl Med. 2014 Jul 16;6(245):245ra93. doi: 10.1126/scitranslmed.3008973.

39.

Epac contributes to cardiac hypertrophy and amyloidosis induced by radiotherapy but not fibrosis.

Monceau V, Llach A, Azria D, Bridier A, Petit B, Mazevet M, Strup-Perrot C, To TH, Calmels L, Germaini MM, Gourgou S, Fenoglietto P, Bourgier C, Gomez AM, Escoubet B, Dörr W, Haagen J, Deutsch E, Morel E, Vozenin MC.

Radiother Oncol. 2014 Apr;111(1):63-71. doi: 10.1016/j.radonc.2014.01.025. Epub 2014 Apr 7.

PMID:
24721545
40.

MiR-210: A potential therapeutic target against radiation-induced enteropathy.

Hamama S, Noman MZ, Gervaz P, Delanian S, Vozenin MC.

Radiother Oncol. 2014 May;111(2):219-21. doi: 10.1016/j.radonc.2013.10.030. Epub 2013 Nov 26.

PMID:
24290534
41.

The combination of the antiviral agent cidofovir and anti-EGFR antibody cetuximab exerts an antiproliferative effect on HPV-positive cervical cancer cell lines' in-vitro and in-vivo xenografts.

Deberne M, Levy A, Mondini M, Dessen P, Vivet S, Supiramaniam A, Vozenin MC, Deutsch E.

Anticancer Drugs. 2013 Jul;24(6):599-608. doi: 10.1097/CAD.0b013e3283612a71.

PMID:
23698251
42.

Enhanced sensitivity to low dose irradiation of ApoE-/- mice mediated by early pro-inflammatory profile and delayed activation of the TGFβ1 cascade involved in fibrogenesis.

Monceau V, Meziani L, Strup-Perrot C, Morel E, Schmidt M, Haagen J, Escoubet B, Dörr W, Vozenin MC.

PLoS One. 2013;8(2):e57052. doi: 10.1371/journal.pone.0057052. Epub 2013 Feb 22.

43.

Therapeutic management of intestinal fibrosis induced by radiation therapy: from molecular profiling to new intervention strategies et vice et versa.

Hamama S, Delanian S, Monceau V, Vozenin MC.

Fibrogenesis Tissue Repair. 2012 Jun 6;5(Suppl 1):S13. doi: 10.1186/1755-1536-5-S1-S13. eCollection 2012.

44.

Radiation-induced enteropathy: molecular basis of pentoxifylline-vitamin E anti-fibrotic effect involved TGF-β1 cascade inhibition.

Hamama S, Gilbert-Sirieix M, Vozenin MC, Delanian S.

Radiother Oncol. 2012 Dec;105(3):305-12. doi: 10.1016/j.radonc.2012.08.023. Epub 2012 Sep 27.

PMID:
23021793
45.

Pharmacological strategies to spare normal tissues from radiation damage: useless or overlooked therapeutics?

Bourgier C, Levy A, Vozenin MC, Deutsch E.

Cancer Metastasis Rev. 2012 Dec;31(3-4):699-712. doi: 10.1007/s10555-012-9381-9. Review.

PMID:
22706781
46.

Normal tissues toxicities triggered by combined anti-angiogenic and radiation therapies: hurdles might be ahead.

Mangoni M, Vozenin MC, Biti G, Deutsch E.

Br J Cancer. 2012 Jul 10;107(2):308-14. doi: 10.1038/bjc.2012.236. Epub 2012 Jun 12.

47.

Bioluminescent orthotopic mouse models of human localized non-small cell lung cancer: feasibility and identification of circulating tumour cells.

Mordant P, Loriot Y, Lahon B, Castier Y, Lesèche G, Soria JC, Vozenin MC, Decraene C, Deutsch E.

PLoS One. 2011;6(10):e26073. doi: 10.1371/journal.pone.0026073. Epub 2011 Oct 11.

48.

[Radiobiology: a multidisciplinary interface].

Deutsch E, Vozenin MC.

Cancer Radiother. 2011 Aug;15(5):347. doi: 10.1016/j.canrad.2011.07.238. French. No abstract available.

PMID:
21835359
49.

[Cancer stem cells: a new target for lung cancer treatment].

Rivera S, Rivera C, Loriot Y, Hennequin C, Vozenin MC, Deutsch E.

Cancer Radiother. 2011 Aug;15(5):355-64. doi: 10.1016/j.canrad.2011.03.003. Epub 2011 Jun 12. Review. French.

PMID:
21664165
50.

[Pharmacological modulation of late radio-induced side effects].

Bourgier C, Monceau V, Bourhis J, Deutsch E, Vozenin MC.

Cancer Radiother. 2011 Aug;15(5):383-9. doi: 10.1016/j.canrad.2011.01.008. Epub 2011 May 18. French.

PMID:
21596606

Supplemental Content

Loading ...
Support Center